Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Janux Therapeutics’s reported figures.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
FAQ
- What is Janux Therapeutics's EBIT?
- Janux Therapeutics (JANX) reported EBIT of -$31.69M in Q2 2026.
- How has Janux Therapeutics's EBIT changed year-over-year?
- Janux Therapeutics's EBIT increased by 29.8% year-over-year, from -$45.12M to -$31.69M.
- What is the long-term trend for Janux Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Janux Therapeutics's EBIT has grown at a 47.9% compound annual growth rate (CAGR), from -$32.93M to -$157.67M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Janux Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude